For those with mild to moderate chronic obstructive pulmonary disease (COPD), researchers suggest that antibiotic stewardship focus on reducing and optimizing antibiotic use in patients with severe COPD who have a significant risk of drug resistance, according to study findings.
For those with mild to moderate chronic obstructive pulmonary disease (COPD), researchers suggest that antibiotic stewardship focus on reducing and optimizing antibiotic use in patients with severe COPD who have a significant risk of drug resistance, according to October study findings published in the Journal of Antimicrobial Chemotherapy.
In 2015, patients with COPD accounted for 11.5% of all antibiotics prescribed, despite being only 2.6% of represented patients in primary care. Compared to those with severe COPD, patients with mild to moderate COPD use fewer antibiotics, however, they make up the majority of patients with COPD.
To find the most effective method of reducing antibiotic use, researchers examined antibiotic prescription statistics to find the optimal target group:
Researchers found that patients with severe COPD were prescribed 6 to 9 prescriptions per year, accounting for 13% of antibiotics prescribed. This is in contrast to those with mild to severe COPD, who received 1 to 3 prescriptions per year but accounted for 42.5% of all prescriptions. According to researchers, targeting patients with moderate to low COPD would be the most effective method of reducing antibiotic use.
“Almost every patient with at least 1 acute exacerbation of COPD (AECOPD) was treated with an antibiotic during follow-up and even patients without a record of AECOPD received at least twice the number of antibiotics compared with the general population, highlighting the heavy use of antibiotics in patients with COPD,” said the study authors.
Study authors note that it remains difficult for general practitioners to distinguish between bacterial and non-bacterially medicated exacerbations, and the decision to prescribe antibiotics depends on the general practitioner’s experience and clinical judgment. However, study findings suggest that patients with mild to severe COPD are ideal for delayed antibiotic prescribing, making them an effective target for antibiotic reduction.
Reference
Rockenschaub P, Jhass A, Freemantle N, et al. Opportunities to reduce antibiotic prescribing for patients with COPD in primary care: a cohort study using electronic health records from the Clinical Practice Research Datalink (CPRD). [published online October 9, 2019]. J Antimicrob Chemother. doi: 10.1093/jac/dkz411.
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Opioids, Benzodiazepines Linked to Higher Mortality in Older Patients With COPD
September 30th 2024A study found that opioid use, with or without benzodiazepines, significantly increases long-term mortality risk in patients with chronic obstructive pulmonary disease (COPD) over the age of 60 years.
Read More
FDA Approves Dupilumab as First Biologic Treatment for COPD
September 27th 2024The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
Read More